Sector: MedicalGENTIUM SPA ADS (NASDAQ: GENT)
Headlines
- Gentium Announces Management Changes and Corporate Restructuring
Mar 01, 2010 07:31 AM | GENT
- Gentium Announces an Abstract for Defibrotide in the Prevention of Hepatic VOD has been Granted the Prestigious Van Bekkum Award by the EBMT
Feb 05, 2010 07:30 AM | GENT
- Gentium Announces Extension of License and Supply and Cost Sharing Agreements with Sigma-Tau
Jan 11, 2010 08:57 AM | GENT
- Gentium Announces New Chairman of the Board
Dec 17, 2009 07:30 AM | GENT
- Gentium Announces Final Clinical Trial Results for Defibrotide Presented at the American Society of Hematology Conference
Dec 07, 2009 08:38 PM | GENT
- Gentium Announces Resignation of Chairman of the Board
Dec 07, 2009 07:30 AM | GENT
- Gentium Announces Presentation of Defibrotide Clinical Data at the American Society of Hematology Annual Meeting
Nov 16, 2009 07:30 AM | GENT
- Gentium Announces New Board of Directors and Interim CEO
Nov 09, 2009 07:30 AM | BLUS, GENT, TAP
- Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
Aug 19, 2009 07:30 AM | GENT
- 11 Hot Stocks To Short & Mark Cuban Getting Caught For Insider Trading On Copernic Inc. (CNIC)
Nov 17, 2008 01:29 PM | DFT, FUQI, GENT
- Gentium Reports Third Quarter Financial Results; Provides Financial Update
Nov 30, 2009 07:51 AM | GENT
- Gentium Reports Second Quarter Financial Results; Provides Financial and Clinical Update
Sep 17, 2009 07:52 AM | GENT
- Gentium Announces Director Resignations and Other Governance Changes
Aug 06, 2009 07:33 AM | GENT
- Gentium Reports First Quarter Financial Results; Provides Financial and Clinical Update
Jun 04, 2009 04:54 PM | GENT
- Gentium Reports 2008 Financial Results; Provides Financial Update
Mar 31, 2009 04:05 PM | GENT
- Gentium Announces Preliminary Results from a Phase 2/3 European Pediatric Prevention Trial for Veno-Occlusive Disease at the European Group for Blood and Marrow Transplantation Annual Meeting
Mar 29, 2009 03:21 AM | GENT
- Gentium Reports Third Quarter Financial Results; Provides Financial Update
Mar 10, 2009 04:31 PM | GENT
- Gentium Announces Completion of Enrollment for the Phase II/III European Pediatric Prevention Trial of Defibrotide
Jan 22, 2009 07:31 AM | GENT
- Gentium Reports Second Quarter Financial Results; Provides Phase II/III Pediatric Prevention Trial and Financial Update
Dec 17, 2008 04:01 PM | GENT
- Gentium Provides an Update on the Phase 3 Treatment Trial of
Defibrotide for Severe Veno-Occlusive Disease
Nov 19, 2008 04:02 PM | GENT
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
GENT
|
Compare to S&P
|
| YTD |
-33.33 %
|
-35.36 %
|
| 4 Weeks |
-16.67 %
|
-22.06 %
|
| 12 Weeks |
-32.13 %
|
-34.93 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 36.36 %
|
|
EPS Growth in Last Year: -3.70 %
|
|
Sales Growth in Last Quarter: 1.02 %
|
|
Sales Growth in Last Quarter: 4.77 %
|
|
